Centessa Pharmaceuticals plc

Equities

CNTA

US1523091007

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 19:57:49 23/05/2024 BST			5-day change	1st Jan Change
8.355 ^USD	-4.51%		-6.82%	+4.77%

05-13	Centessa Pharmaceuticals plc Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
04-24	Exchange-Traded Funds Higher, Equity Futures Mixed Pre-Bell Wednesday Amid Earnings Deluge	MT

Centessa Pharmaceuticals plc Reports Earnings Results for the First Quarter Ended March 31, 2023

May 12, 2023 at 12:15 pm

Centessa Pharmaceuticals plc reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported net loss was USD 50.71 million compared to USD 54.5 million a year ago. Basic loss per share from continuing operations was USD 0.53 compared to USD 0.6 a year ago.

Latest news about Centessa Pharmaceuticals plc

Centessa Pharmaceuticals plc Reports Earnings Results for the First Quarter Ended March 31, 2024	05-13	CI
Exchange-Traded Funds Higher, Equity Futures Mixed Pre-Bell Wednesday Amid Earnings Deluge	04-24	MT
Centessa Pharmaceuticals Prices Equity Offering at $9.25 Per ADS	04-24	MT
Centessa Pharmaceuticals Eyes $100 Million in ADS Offering	04-23	MT
Centessa Pharmaceutical Gets FDA's Approval to Begin Phase 1 Trial of Narcolepsy Drug Candidate	04-22	MT
Centessa Pharmaceuticals plc Announces Open IND for ORX750	04-22	CI
Centessa Pharmaceuticals plc Reports Earnings Results for the Full Year Ended December 31, 2023	03-28	CI
Centessa Pharmaceuticals plc Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-28	CI
Centessa Pharmaceuticals Insider Sold Shares Worth $607,960, According to a Recent SEC Filing	03-26	MT
ADRs End Lower, WISekey International Holding Ltd. Declines 17.3%	01-17	DJ
Centessa Pharmaceuticals plc Announces New Data from an Additional 52-Weeks of Continuous Treatment from Third Year (Part 5) of Ongoing Phase 2A Study of Serpinpc for the Treatment of Hemophilia	12-10	CI
AnaptysBio Secures Exclusive License for Centessa's BDCA2 Modulator Antibody Portfolio	11-27	MT
Anaptysbio, Inc. Enters into License Agreement with Centessa Pharmaceuticals (UK) Limited	11-27	CI
Centessa Pharmaceuticals' Q3 Loss Narrows	11-13	MT
Centessa Pharmaceuticals plc Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-13	CI
Centessa Pharmaceuticals plc Announces Dosing of First Subject in Registrational Present-3 Study Evaluating Serpinpc for the Treatment of Hemophilia B with Inhibitors	31/10/23	CI
Morgan Stanley Upgrades Centessa Pharmaceuticals to Equalweight From Underweight, Doubles Price Target to $8 From $4 on 'Encouraging' Preclinical Data on Narcolepsy Treatment Candidate	26/10/23	MT
Centessa Pharmaceuticals plc Announces Preclinical Data Supporting Orx750's Potential as A Best-In-Class Oral Ox2r Agonist for the Treatment of Narcolepsy and Other Sleep-Wake Disorders	25/10/23	CI
Centessa Pharmaceuticals plc Announces Executive Appointments	04/10/23	CI
ADRs Slump, The9 Ltd. Declines 28.9%	02/10/23	DJ
Centessa Pharmaceuticals Insider Sold Shares Worth $235,688, According to a Recent SEC Filing	22/09/23	MT
Transcript : Centessa Pharmaceuticals plc Presents at Morgan Stanley 21st Annual Global Healthcare Conference 2023, Sep-12-2023 04:15 PM	12/09/23
World Sleep Congress Releases an Abstract Submit by Centessa Pharmaceuticals plc	24/08/23	CI
Guggenheim Adjusts Price Target on Centessa Pharmaceuticals to $10 From $9, Maintains Buy Rating	15/08/23	MT
Goldman Sachs Adjusts Price Target on Centessa Pharmaceuticals to $5 From $4.50, Maintains Neutral Rating	15/08/23	MT

Chart Centessa Pharmaceuticals plc

Duration

Period

More charts

Company Profile

Centessa Pharmaceuticals plc is a United Kingdom-based clinical-stage pharmaceutical company. Its advanced programs include a hemophilia program, an orexin agonist program for the treatment of narcolepsy and other sleep-wake disorders, and an immuno-oncology program focused on its LockBody technology platform. SerpinPC, its advanced product candidate, is an investigational, potentially first-in-class subcutaneously administered novel inhibitor of activated protein C for hemophilia. Its Orexin Receptor 2 (OX2R) Agonist Program includes ORX750, which is an investigational, orally administered, selective OX2R agonist designed to directly target the underlying pathophysiology of orexin neuron loss in narcolepsy type 1 and to address sleep-wake disorders with normal orexin levels such as narcolepsy type 2 and idiopathic hypersomnia. It is also exploring follow-up orexin agonists for potential expansion opportunities into a range of sleep-wake disorders and broader neurological indications.

Sector

Biotechnology & Medical Research

Calendar

11/06/2024 - Goldman Sachs Global Healthcare Conference

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

8.75 USD

Average target price

13.6 USD

Spread / Average Target

+55.43%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
CENTESSA PHARMACEUTICALS PLC	+4.77%	977M
MODERNA, INC.	+63.99%	62.59B
IQVIA HOLDINGS INC.	-2.01%	41.18B
LONZA GROUP AG	+44.76%	40.29B
CELLTRION, INC.	-8.93%	27.9B
ICON PUBLIC LIMITED COMPANY	+12.50%	26.21B
ALNYLAM PHARMACEUTICALS, INC.	-21.93%	19.09B
BIO-TECHNE CORPORATION	+3.88%	13.08B
UNITED THERAPEUTICS CORPORATION	+25.37%	12.26B
MEDPACE HOLDINGS, INC.	+27.38%	12.05B

Other Biotechnology & Medical Research